Table 1.
Assessment of the quality of the eligible studies based on NOS.
| Case control study | Selection | Comparability 5 | Exposure | Total | |||||
|---|---|---|---|---|---|---|---|---|---|
| Definition 1 | Representative-ness 2 | Selection 3 | Definition 4 | Ascertainment 6 | Method 7 | Rate 8 | |||
| Huang et al (2008) | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 6 |
| Liu et al (2015) | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 5 |
| Ott et al (2006) | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 6 |
| Ott et al (2011) | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 6 |
| Roberto et al (2017) | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 6 |
| Shitara et al (2010) | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 5 |
| Zhao et al (2016) | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 5 |
| Cohort study | Selection | Comparability 5 | Outcome | Total | |||||
| Representative-ness 9 | Selection 10 | Ascertainment 6 | Demonstration 11 | Assessment 12 | Duration 13 | Adequacy 14 | |||
| Chen et al (2010) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Gao et al (2004) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Goekkurt et al (2009) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Meulendijks 1 et al 15 (2016) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Meulendijks 2 et al 16 (2016) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Ruzzo et al (2006) | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
1Adequate definition of cases (0, 1); 2Consecutive or obviously representative series of cases (0, 1); 3Selection of controls: Community controls (0, 1); 4Definition of controls: No history of disease (0, 1); 5Study controls for the most important factor or any additional factor (0, 1, 2); 6Secure record (0, 1); 7Same method of ascertainment for cases and controls (0, 1); 8Same non-response rate for both groups (0, 1);9Truly or somewhat representative of the exposed cohort (0, 1); 10Selection of the non-exposed cohort (0, 1);11Demonstration that outcome of interest was not present at start of study (0, 1); 12Assessment of outcome (0, 1); 13Follow-up long enough for outcomes to occur (0, 1); 14Adequacy of follow up of cohorts (0, 1); 15Meulendijks 1 et al represents article published by this author in the journal Cancer; 16Meulendijks 2 et al represents article published by this author in the journal Pharmacogenomics.